Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients

Human gamma interferon (HuIFN gamma) was assessed for its capacity to enhance release of granulocyte-macrophage colony stimulating factors (GM-CSF) from human peripheral blood monocytes. Natural HuIFN gamma (2 X 10(7) NIH reference units per milligram) at concentrations as low as 0.01 U/mL to 10 U/mL reproducibly enhanced release of GM-CSF. This enhancement was detected when T lymphocytes were depleted from monocyte preparations and when T lymphocytes and monocytes were depleted from populations of human bone marrow cells stimulated by monocyte- conditioned media to form colonies and clusters. T lymphocytes alone or in the presence of HuIFN gamma did not release GM-CSF. The enhancing activity of HuIFN gamma was removed by preincubating HuIFN gamma with neutralizing concentrations of monoclonal anti-HuIFN gamma, and recombinant HuIFN gamma mimicked the effects of natural HuIFN gamma, suggesting that the effects were due to HuIFN gamma itself. HuIFN gamma suppression of the release of inhibitory activity from monocytes was ruled out as a reason for the noted enhancing activity of HuIFN gamma. The enhancing activity of HuIFN gamma was confined to the MHC class II antigen-positive population of monocytes. Removal of these cells with monoclonal antibody plus complement (c') ablated the enhancing activity, high concentrations of certain monoclonal antibodies in the absence of c' blocked the enhancing activity and, when monocytes were sorted into MHC class II antigen-positive and -negative cells by fluorescence-activated cell sorting, it was only the positive cell fraction that responded to the enhancing activity of HuIFN gamma.

Download Full-text

Efficacy of granulocyte and granulocyte–macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study

The Hematology Journal ◽

10.1038/sj.thj.6200536 ◽

2004 ◽

Vol 5 (5) ◽

pp. 384-394 ◽

Cited By ~ 14

Author(s):

Xavier Thomas ◽

Jean-Michel Boiron ◽

Françoise Huguet ◽

Oumedaly Reman ◽

Laurent Sutton ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Lymphoblastic Leukemia ◽

Randomized Study ◽

Induction Treatment ◽

Colony Stimulating Factors ◽

Adult Acute Lymphoblastic Leukemia ◽

Macrophage Colony

Download Full-text

Granulocyte-macrophage colony-stimulating factors

Reactions Weekly ◽

10.2165/00128415-200711800-00057 ◽

2007 ◽

Vol &NA; (1180) ◽

pp. 19

Author(s):

&NA;

Keyword(s):

Colony Stimulating Factors ◽

Macrophage Colony

Download Full-text

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma

Advances in Hematology ◽

10.1155/2011/656013 ◽

2011 ◽

Vol 2011 ◽

pp. 1-7 ◽

Cited By ~ 2

Author(s):

Bhanu Vakkalanka ◽

Brian K. Link

Keyword(s):

Effective Treatment ◽

Hodgkin Lymphoma ◽

Significant Risk ◽

Therapeutic Use ◽

Colony Stimulating Factors ◽

Definitive Evidence ◽

Dose Modification ◽

Chemotherapy Regime ◽

Highly Effective ◽

Abvd Chemotherapy

A combination of Adriamycin (a.k.a. Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine (ABVD) is the most commonly used chemotherapy regime for Hodgkin lymphoma. This highly effective treatment is associated with a significant risk of neutropenia. Various strategies are adopted to counter this commonly encountered problem, including dose modification, use of colony stimulating factors, and prophylactic or therapeutic use of antibiotics. Data to support these approaches is somewhat controversial, and in keeping with the paucity of definitive evidence, there is a wide disparity in the management of neutropenia in patients receiving ABVD chemotherapy. This paper summarizes the evidence for managing ABVD-related neutropenia during the treatment of Hodgkin lymphoma.

Download Full-text